Truths and Misconceptions About FDA’s Compounding MOU
Earlier this month, FDA announced it will provide states one more year to decide whether to sign its compounding memorandum of understanding (MOU) before the agency begins enforcing the statutory 5% limit on out-of-state distribution of compounded human drug products. This comes after many states asked for more time to wrangle with the legal and […]
Read More ›We Offer Helping Hand to States Building Drug Importation Plans
Prescription drug prices continue soaring and no light is visible at the end of the tunnel. Wanting to bring relief to cash-strapped constituents, many states are creating their own drug importation programs from Canada using an FDA rule finalized in November 2020. Regulating these systems will be complex, but states do not have to go it alone. That’s why I’m focusing my term as NABP President on helping them navigate the process to ensure the integrity of the drug […]
Read More ›To Protect Public Health, NABP Clearinghouse Helps Boards Track Administrative and Disciplinary Data
One of the most important responsibilities a board of pharmacy has is ensuring its thousands of pharmacists, pharmacy interns, pharmacy technicians, facilities, and more practice safely and legally. This is a daunting task within itself, but we have a tool that can help. NABP Clearinghouse eases the workload. It’s a national database of disciplinary and […]
Read More ›Pharmacy Regulation Buff? A New NABP Committee Could Use Your Help
NABP’s task forces and committees offer board of pharmacy members and staff the chance to shape our programs and services. One of our newest committees will ensure that our member boards of pharmacy have the regulatory tools they need to protect their constituents’ health. The Model Act Review Committee will evaluate the Model State Pharmacy […]
Read More ›The Future of Telehealth and the Ryan Haight Act Post-Pandemic
A year into the pandemic, and coronavirus disease 2019 (COVID-19) has radically changed our health care system from the pace at which new drugs come to market to how patients access health care and medications. Arguably one of the most dramatic shifts has been the major increase in telehealth usage and the expansion of services […]
Read More ›NABP, FDA Collaborate to Improve Compounding Pharmacy Oversight
In 2012, many of the people who received contaminated steroid injections produced at the New England Compounding Center had already been suffering from chronic pain. The compounded drugs were supposed to provide relief. Instead, they infected these patients with fungal meningitis, killing 64 and sickening 753. The tragedy was a wakeup call for regulators, […]
Read More ›Access to Treatment for Opioid Use Disorder Is Limited by Unnecessary Regulations
Across the country, officials are reporting spikes in drug overdoses as the opioid epidemic is exacerbated by the COVID-19 pandemic. The Centers for Disease Control and Prevention recently reported the highest number of overdose deaths ever recorded in a 12-month period – 81,000 people. Access to opioid use disorder treatment could help save the lives […]
Read More ›Why the White Pages of the Internet Matters to Public Health
This week, members of the Coalition for a Secure and Transparent Internet (CSTI) – including NABP – will virtually take to Capitol Hill to meet with members of Congress to discuss restoring access to WHOIS data. NABP and other CSTI members will speak with congressional staff about how essential this data is to law enforcement […]
Read More ›Countdown Clock Begins on Importation Rule Enactment
Following an expeditious review by the White House Office of Management and Budget, Food and Drug Administration (FDA) formally published its final rule regarding Importation of Prescription Drugs in the Federal Register on Thursday, October 1, 2020. The publication of the final rule starts the 60-day formal notice-and-comment period before the rule becomes effective on Monday, November 30. The […]
Read More ›White House Completes Review of Importation Final Rule
On Thursday, September 10, Food and Drug Administration (FDA) sent a proposed final rule to the White House Office of Management and Budget (OMB) for review that would set in motion components of the long-awaited Safe Importation Action Plan released in July 2019. Completion of this final rule has been a long-standing priority for FDA and the […]
Read More ›